Cell-Based Gene Transfer of Vascular Endothelial Growth Factor Attenuates Monocrotaline-Induced Pulmonary Hypertension
- 30 October 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (18) , 2242-2248
Abstract
Background Pulmonary arterial hypertension is characterized by increased pulmonary vascular resistance secondary to a decrease in the caliber and number of pulmonary vascular channels. We hypothesized that the targeted overexpression of an angiogenic factor within the lung would potentially minimize the development and progression of pulmonary arterial hypertension by preventing the loss of existing vessels or by inducing the development of new blood vessels within the lung. Methods and Results We used a cell-based method of gene transfer to the pulmonary microvasculature by delivering syngeneic smooth muscle cells overexpressing vascular endothelial growth factor (VEGF)-A to inbred Fisher 344 rats in which pulmonary hypertension was induced with the pulmonary endothelial toxin monocrotaline. Four weeks after simultaneous endothelial injury and cell-based gene transfer, right ventricular (RV) hypertension and RV and vascular hypertrophy were significantly decreased in the VEGF-treated animals. Four weeks after gene transfer, the plasmid VEGF transcript was still detectable in the pulmonary tissue of animals injected with VEGF-transfected cells, demonstrating survival of the transfected cells and persistent transgene expression. In addition, delay of cell-based gene transfer until after the development of pulmonary hypertension also resulted in a significant decrease in the progression of RV hypertension and hypertrophy. Conclusions These results indicate that cell-based VEGF gene transfer is an effective method of preventing the development and progression of pulmonary hypertension in the monocrotaline model and suggest a potential therapeutic role for angiogenic factors in the therapy of this devastating disease.Keywords
This publication has 27 references indexed in Scilit:
- Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertensionThe FASEB Journal, 2001
- Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor–II GeneThe American Journal of Human Genetics, 2000
- Cell-Based Gene Transfer to the Pulmonary VasculatureAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- Prognoses of Primary Pulmonary Hypertension and Chronic Majorvessel Thromboembolic Pulmonary Hypertension Determined from Cumulative Survival Curves.Internal Medicine, 1999
- Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction PathwayJournal of Biological Chemistry, 1998
- VEGF-A Induces Expression of eNOS and iNOS in Endothelial Cells via VEGF Receptor-2 (KDR)Biochemical and Biophysical Research Communications, 1998
- Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.Journal of Clinical Investigation, 1997
- Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32Nature Genetics, 1997
- Safety and Toxicity of Catheter Gene Delivery to the Pulmonary Vasculature in a Patient with Metastatic MelanomaHuman Gene Therapy, 1994
- Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertensionBiochemical Pharmacology, 1993